Targeting mitocytosis potentiates mitochondria drug delivery for antimetastasis therapy
Science Advances · 2026
DOI: 10.1126/sciadv.aec7150 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Yudi Deng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-So…. Hauptthemen laut MEDLINE: Mitochondria, Drug Delivery Systems, Antineoplastic Agents, Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National key R&D program of China, Regional Innovation and Development Joint Fund.
Abstract (Originalsprache)
Mitocytosis is a compensatory pathway responding to mitochondria stress in migratory cells, which expels damaged mitochondria through migrasomes, preserving mitochondrial homeostasis and cellular viability. We found distinct responses to mitochondria-targeted therapy across breast tumor models distinguished by migrasome expression (4T1 > E0771 > EMT6). The antimetastatic efficacy of mitochondrial damage was notably compromised in the migrasome-high 4T1 tumor model due to robust mitocytosis activation, which is merely explored and lacks effective strategy. Here, we developed a mitochondria-targeted nanoplatform (RH-NPs) with the functions of mitocytosis inhibition and mitochondrial damage. Mitochondria-targeted triphenylphosphonium-modified lonidamine (TPP-LND) and integrin inhibitor cilengitide (CGT) were separately loaded into a nanodelivery system (TL/RH-NPs and CGT/RH-NPs, respectively). TL/RH-NPs effectively targeted and damaged tumor mitochondria. Simultaneously, upon mitocytosis activation, CGT/RH-NPs hitchhiked with damaged mitochondria into migrasomes to block mitocytosis via integrin inhibition. This strategy significantly potentiated antimetastatic efficacy in 4T1 tumor models, which established an effective approach for mitocytosis modulation and optimization of mitochondria-targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial T…
ORCID-Profile: Yudi Deng, Peihang Jiang, Lian Li, Yuan Huang
Förderung
- National key R&D program of China
- Regional Innovation and Development Joint Fund
Zitieren
APA
Deng, Y., Zhang, Y., Jia, F., Jiang, P., Li, L., & Huang, Y. (2026). Targeting mitocytosis potentiates mitochondria drug delivery for antimetastasis therapy. Science Advances. https://doi.org/10.1126/sciadv.aec7150
Vancouver
Deng Y, Zhang Y, Jia F, Jiang P, Li L, Huang Y. Targeting mitocytosis potentiates mitochondria drug delivery for antimetastasis therapy. Science Advances. 2026. doi:10.1126/sciadv.aec7150
BibTeX
@article{Deng2026,
author = {Deng, Yudi and Zhang, Yunhui and Jia, Fuya and Jiang, Peihang and Li, Lian and Huang, Yuan},
title = {Targeting mitocytosis potentiates mitochondria drug delivery for antimetastasis therapy},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aec7150}
}
EUVIMED